ENSC Logo

Ensysce Biosciences, Inc. (ENSC) 

NASDAQ
Market Cap
$7.37M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
656 of 963
Rank in Industry
364 of 552

Largest Insider Buys in Sector

ENSC Stock Price History Chart

ENSC Stock Performance

About Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Insider Activity of Ensysce Biosciences, Inc.

Over the last 12 months, insiders at Ensysce Biosciences, Inc. have bought $0 and sold $0 worth of Ensysce Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Ensysce Biosciences, Inc. have bought $370,327 and sold $8.1M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 90,287 shares for transaction amount of $44,087 was made by GOWER BOB G (director) on 2023‑03‑02.

List of Insider Buy and Sell Transactions, Ensysce Biosciences, Inc.

2023-03-02Purchasedirector
90,287
0.6576%
$0.49$44,087-71.07%
2023-03-01Purchasedirector
270,000
2.1241%
$0.48$128,979-68.06%
2023-02-28Purchasedirector
109,300
0.8628%
$0.49$53,371-68.47%
2022-12-09Purchasedirector
357,143
19.2974%
$1.40$500,000-83.82%
2022-05-25PurchaseChief Executive Officer
27,000
0.0797%
$0.53$14,216-78.38%
2020-06-19Sale10 percent owner
776,290
0.2223%
$10.44$8.1M-4.82%
2017-12-01Purchase10 percent owner
1M
4.2688%
$10.00$10M+28324.91%

Insider Historical Profitability

<0.0001%
HG Vora Capital Management, LLC10 percent owner
3837500
294.0771%
$5.6510
GOWER BOB Gdirector
1222682
93.6971%
$5.6540<0.0001%
Kirkpatrick LynnChief Executive Officer
381851
29.2622%
$5.6510
MORGAN STANLEY10 percent owner
0
0%
$5.6501

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.